

Date: February 25, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Acquisition of 3000 Equity Shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals - Subsidiary of the Company

With reference to our earlier intimation dated January 23, 2025 regarding in-principal approval accorded by the Board of Directors of the Senores Pharmaceuticals Limited (“the Company” or “the Purchaser”) for acquisition of certain number of equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix” or “the Target Company”) held by Senores Pharmaceuticals Inc., Wholly Owned Subsidiary of the Company (“SPI” or “the Seller”). In this regard, we would like to inform that as per the approval accorded by the Management Committee of Board of Directors of the Company, in their meeting held today i.e. February 25, 2025, the Company has entered into the Share Purchase Agreement (“SPA”) with the SPI for acquisition of 3000 (Three Thousand) equity shares of Havix aggregating to 1.32 % of the total paid up share capital of the Target Company and subject to the terms and conditions as mentioned in the SPA.

Further, post the aforesaid acquisition, the shareholding of the Company in Havix will increase from 49.91% to 51.23%.

We have enclosed herewith the details required under Regulation 30 read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1**.

We request you to take the above information on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

Annexure - 1
Disclosure under Regulation 30(6) read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix") is currently engaged in the business of developing, manufacturing and supplying of various finished formulations. The turnover of Havix for the financial year ended March 31, 2024 was USD 14,440,414.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The shares of Havix are being acquired from SPI, which is a Wholly Owned Subsidiary and hence a related party of the Company. Therefore, the transaction falls within the ambit of related party transactions and is at arms' length.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	SPL, at present holds 49.91% of equity shares of Havix and the aforesaid acquisition of 3000 equity shares is being done to consolidate the direct holding of the Company in Havix, -a subsidiary of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Requisite approvals under Foreign Exchange Management Act, 1999 have been applied for.
6.	Indicative time period for completion of the acquisition	Within period 10 days from the date of execution of SPA.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	USD 160 per equity share.
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	3000 (Three Thousand) equity shares constituting 1.32%, of the total paid up share capital of the Target Company.

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

Sr. No.	Particulars	Description						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Havix was incorporated under the laws of the State of Delaware on February 17, 2015. Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations.</p> <p>The turnover of Havix for last 3 years is given below:</p> <p style="text-align: right;">(Amount in USD)</p> <table border="1" data-bbox="862 478 1414 583"> <thead> <tr> <th data-bbox="862 478 1036 531">Mar-22</th> <th data-bbox="1036 478 1224 531">Mar-23</th> <th data-bbox="1224 478 1414 531">Mar-24</th> </tr> </thead> <tbody> <tr> <td data-bbox="862 531 1036 583">7,336,642</td> <td data-bbox="1036 531 1224 583">8,814,761</td> <td data-bbox="1224 531 1414 583">14,440,414</td> </tr> </tbody> </table> <p>Country of presence: United States of America</p>	Mar-22	Mar-23	Mar-24	7,336,642	8,814,761	14,440,414
Mar-22	Mar-23	Mar-24						
7,336,642	8,814,761	14,440,414						

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263